Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma

2016 ◽  
Vol 59 (5) ◽  
pp. 1727-1746 ◽  
Author(s):  
Stuart T. Onions ◽  
Kazuhiro Ito ◽  
Catherine E. Charron ◽  
Richard J. Brown ◽  
Marie Colucci ◽  
...  
Keyword(s):  
Kinase Inhibitors ◽  
Therapeutic Agents ◽  
Steroid Resistant ◽  
Narrow Spectrum

scholarly journals How I treat hypereosinophilic syndromes

Blood ◽  
2009 ◽  
Vol 114 (18) ◽  
pp. 3736-3741 ◽  
Author(s):  
Amy D. Klion
Keyword(s):  
Kinase Inhibitors ◽  
Therapeutic Agents ◽  
Peripheral Eosinophilia ◽  
Therapeutic Decisions ◽  
Organ Manifestations ◽  
Diagnosis And Classification ◽  
Humanized Monoclonal Antibodies ◽  
Peripheral Blood Eosinophilia

Abstract Hypereosinophilic syndromes (HESs) are a heterogeneous group of uncommon disorders characterized by marked peripheral eosinophilia and end organ manifestations attributable to the eosinophilia or unexplained in the clinical setting. Whereas corticosteroids remain the mainstay of treatment for most patients, recent diagnostic advances and the development of novel targeted therapies, including tyrosine kinase inhibitors and humanized monoclonal antibodies, have increased the complexity of therapeutic decisions in HESs. This review presents a treatment-based approach to the diagnosis and classification of patients with peripheral blood eosinophilia of 1.5 × 109/L (1500/mm3) or higher and discusses the role of currently available therapeutic agents in the treatment of these patients.

scholarly journals Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011–2020): Current Status and Future Prospects

Molecules ◽  
2022 ◽  
Vol 27 (1) ◽  
pp. 330
Author(s):  
Mohammed I. El-Gamal ◽  
Seyed-Omar Zaraei ◽  
Moustafa M. Madkour ◽  
Hanan S. Anbar
Keyword(s):  
Kinase Inhibitors ◽  
Therapeutic Agents ◽  
Current Status ◽  
Pyrazole Derivatives ◽  
Chronological Order ◽  
Pharmacological Activities ◽  
The Past ◽  
Cancer Types ◽  
Privileged Scaffold ◽  
Almost All

Pyrazole has been recognized as a pharmacologically important privileged scaffold whose derivatives produce almost all types of pharmacological activities and have attracted much attention in the last decades. Of the various pyrazole derivatives reported as potential therapeutic agents, this article focuses on pyrazole-based kinase inhibitors. Pyrazole-possessing kinase inhibitors play a crucial role in various disease areas, especially in many cancer types such as lymphoma, breast cancer, melanoma, cervical cancer, and others in addition to inflammation and neurodegenerative disorders. In this article, we reviewed the structural and biological characteristics of the pyrazole derivatives recently reported as kinase inhibitors and classified them according to their target kinases in a chronological order. We reviewed the reports including pyrazole derivatives as kinase inhibitors published during the past decade (2011–2020).

Phospho-Flow Cytometry: A Method for Investigating Effects of Narrow Spectrum Kinase Inhibitors on Kinase Phosphorylation as a Clinical Biomarker

2017 ◽  
Vol 152 (5) ◽  
pp. S767
Author(s):  
Sameer Sirohi ◽  
Martyn Foster ◽  
Matthew C. Fyfe ◽  
Yemisi Solanke ◽  
Steve Webber ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Kinase Inhibitors ◽  
Narrow Spectrum ◽  
Clinical Biomarker ◽  
Kinase Phosphorylation

scholarly journals Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis

2016 ◽  
Vol 22 (6) ◽  
pp. 1306-1315 ◽  
Author(s):  
Paolo Biancheri ◽  
Martyn R. Foster ◽  
Matthew C. T. Fyfe ◽  
Thomas T. MacDonald ◽  
Sameer Sirohi ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Immune Response ◽  
Kinase Inhibitors ◽  
Narrow Spectrum ◽  
Spectrum Versus

Interleukin-1 receptor associated kinase inhibitors: Potential therapeutic agents for inflammatory- and immune-related disorders

2015 ◽  
Vol 27 (6) ◽  
pp. 1039-1055 ◽  
Author(s):  
Malkeet Singh Bahia ◽  
Maninder Kaur ◽  
Pragati Silakari ◽  
Om Silakari
Keyword(s):  
Kinase Inhibitors ◽  
Interleukin 1 ◽  
Therapeutic Agents
Sign in / Sign up

Export Citation Format

Share Document